Search research articles
Contact Us
Filters
Showing results (31-40 of 52) with videos related to
Page
of 6
Sort By:
The New England Journal of Medicine
|
September 4, 2024
Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Frontiers in Oncology
|
August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
British Journal of Cancer
|
November 2, 2023
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study
Florence Duffaud, Jean-Yves Blay, Axel Le Cesne, et al.
The Lancet. Oncology
|
July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Gynecologic Oncology
|
November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial
Clémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
Ursula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.
Gynecologic Oncology
|
February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study
Florence Joly, Michel Fabbro, Philippe Follana, et al.
Bulletin Du Cancer
|
March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]
Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Nature Communications
|
July 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, et al.
Cancers
|
January 21, 2022
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network
Clémence Romeo, Olivia Le Saux, Margaux Jacobs, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 52) with videos related to
Sort By:
Page
of 6
The New England Journal of Medicine
|
September 4, 2024
Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Frontiers in Oncology
|
August 5, 2022
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T<sub>H</sub>1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotevi, et al.
British Journal of Cancer
|
November 2, 2023
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study
Florence Duffaud, Jean-Yves Blay, Axel Le Cesne, et al.
The Lancet. Oncology
|
July 14, 2022
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, et al.
Gynecologic Oncology
|
November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial
Clémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
Ursula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.
Gynecologic Oncology
|
February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study
Florence Joly, Michel Fabbro, Philippe Follana, et al.
Bulletin Du Cancer
|
March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]
Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Nature Communications
|
July 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, et al.
Cancers
|
January 21, 2022
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG Network
Clémence Romeo, Olivia Le Saux, Margaux Jacobs, et al.
Page
of 6